NICE invites comments from the public on the draft guidance to not recommend the parp inhibitor talazoparib

METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with

METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS.

METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)

Philippa Hetherington Remembered

We had to confirm back on the 5th November the heartbreaking news that the wonderful Philippa Hetherington had died 💔

She was an absolute force of intellectual nature for breast cancer in general, not just Inflammatory Breast Cancer.

Did you know that the Trodelvy campaign in England for TNBC was HER campaign?

Trodelvy Now! Latest Update

Trodelvy Approved by NICE

METUPUK are delighted that NICE has accepted Trodelvy (sacituzumab govitecan) for routine use on the NHS in England for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior lines of systemic therapies. This follows on from the decision to approve Trodelvy in NHS Scotland in March 2022. Wales and Northern Ireland normally follow decisions by NHS England and we hope that Trodelvy will be made available to every patient who is eligible without delay.